Evidence map›Paper›PMID 38883960›Full record

ArticleAnnals of surgery open : perspectives of surgical history, education, and clinical approaches2024

Health Economic Evaluation of Patients With Colorectal Liver Metastases Randomized to ALPPS or TSH: Analysis From the LIGRO Trial.

Kristina Hasselgren, Martin Henriksson, Bård I Røsok, Peter N Larsen, Ernesto Sparrelid, Gert Lindell, Nicolai A Schultz, Bjorn A Bjørnbeth, Bengt Isaksson, Magnus Rizell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kristina HasselgrenFrom the Division of surgery, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Martin HenrikssonCentre for Medical Technology Assessment, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Bård I RøsokDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.
Peter N LarsenDepartment of Surgical Gastroenterology and Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ernesto SparrelidDepartment of Clinical Science, Intervention and Technology, Division of Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Gert LindellDepartment of Surgery, Skane University Hospital, Lund, Sweden.
Nicolai A SchultzDepartment of Surgical Gastroenterology and Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Bjorn A BjørnbethDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.
Bengt IsakssonDepartment of Surgery, Akademiska University Hospital, Uppsala, Sweden.
Magnus RizellDepartment of Transplantation and Liver Surgery, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anna Lindhoff LarssonFrom the Division of surgery, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Per SandströmFrom the Division of surgery, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Bergthor BjörnssonFrom the Division of surgery, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This is a preplanned, health economic evaluation from the LIGRO trial. One hundred patients with colorectal liver metastases (CRLM) and standardized future liver remnant <30% were randomized to associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) or two-staged hepatectomy (TSH). Summary Background Data: TSH, is an established method in advanced CRLM. ALPPS has emerged providing improved resection rate and survival. The health care costs and health outcomes, combining health-related quality of life (HRQoL) and survival into quality-adjusted life years (QALYs), of ALPPS and TSH have not previously been evaluated and compared. Methods: Costs and QALYs were compared from treatment start up to 2 years. Costs are estimated from resource use, including all surgical interventions, length of stay after interventions, diagnostic procedures and chemotherapy, and applying Swedish unit costs. QALYs were estimated by combining survival and HRQoL data, the latter being assessed with EQ-5D 3L. Estimated costs and QALYs for each treatment strategy were combined into an incremental cost-effectiveness ratio (ICER). Nonparametric bootstrapping was used to assess the joint distribution of incremental costs and QALYs. Results: The mean cost difference between ALPPS and TSH was 12,662€, [95% confidence interval (CI): -10,728-36,051; Conclusions: Based on the 2-year data, the cost-effectiveness of ALPPS is uncertain. Further research, exploring cost and health outcomes beyond 2 years is needed.

Indexed as

associating liver partition and portal vein ligation for staged hepatectomycolorectal liver metastaseshealth economic evaluationtwo-staged hepatectomy

Identifiers

PMID38883960
PMCPMC11175926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.